Oric Pharmaceuticals, Inc.
ORIC· Nasdaq
Released Mar 11, 2024, after the close
10-K filed Mar 11, 2024, 71 days after period end · 0000950170-24-029298
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$28.33M | -$20.85M | -$22.77M | -$28.26M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oric Pharmaceuticals, Inc. · CIK 1796280 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2023 · filed Mar 11, 2024 · 71 d after period end
5.0% from the close of Mar 6, 2024 to the close of Mar 13, 2024, the first after the release.